What is it about?

The article describes mechanism and practical considerations by which pharmaceutical molecules can be altered via co-crystallisation to yield useful pharmaceutical phases. The manuscript specifically deals with regulation, screening and production methods for these crystalline phases and looks at important physical properties, beyond simply solubility, for their broader utility in the pharmaceutical sector.

Featured Image

Why is it important?

This article is of significant interest to those who would like to explore the methodologies of co-crystal screening and production, and the broader rationale for doing so in the pharmaceutical context.

Read the Original

This page is a summary of: Pharmaceutical co-crystals – are we there yet?, CrystEngComm, January 2014, Royal Society of Chemistry,
DOI: 10.1039/c4ce00127c.
You can read the full text:

Read

Contributors

The following have contributed to this page